SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is experiencing upward momentum as traders react to positive economic signals, including lower-than-expected jobless claims that have dampened expectations for near-term interest rate hikes. The community remains divided between bullish sentiment, fueled by expectations of institutional adoption and regulatory developments, and skeptics who view the price action as a consolidation or a potential bull trap.

Planet Labs PBC provides daily data and insights about earth. It offers a web-geo platform with satellite data available and foundational analytics to derive insights to make decisions. The company is founded by William S. Marshall and Robert H. Schingler in 2010 and is headquartered in San Francisco, CA.

Planet Labs PBC - Ordinary Shares - Class A

Planet Labs PBC

Planet Labs is trending as traders speculate on a potential earnings leak or institutional manipulation, with significant debate over whether the recent sharp price decline is an opportunity for accumulation or a sign of further downside. The conversation is characterized by high volatility and divided sentiment, with some market participants pointing to institutional buying and backlog growth as long-term bullish indicators, while others remain concerned about management silence and broad sector weakness.

lululemon athletica, Inc. engages in the business of designing, distributing, and retailing technical athletic apparel, footwear, and accessories. It operates through the following segments: Company-Operated Stores, Direct to Consumer, and Other. The company was founded by Dennis James Wilson in 1998 and is headquartered in Vancouver, Canada.

Lululemon Athletica inc.

Lululemon Athletica Inc

Lululemon is trending as traders debate the potential impact of an upcoming earnings report, with sentiment divided between those betting on a value-driven recovery bolstered by institutional accumulation and those fearing further downside amid weakening retail sentiment and management instability. Many investors are specifically focusing on the transition to a new CEO and potential tariff refunds, while others remain skeptical due to broader apparel sector headwinds.

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhood is trending as investors react to a series of positive analyst upgrades and price target hikes, with sentiment buoyed by the company's expanding product ecosystem and prediction market growth. While many traders are optimistic about a potential breakout, some remain skeptical of the stock's performance and allege market manipulation.

Snowflake, Inc. engages in the provision of cloud data warehousing software. The firm offers Data Cloud, an ecosystem where Snowflake customers, partners, data providers, and data consumers can break down data silos and derive value from data. Its platform supports a range of use cases including data warehousing, data lakes, data engineering, data science, data application development, and data sharing. The cloud-native architecture consists of layers across storage, compute, and cloud services. The storage layer ingests structured and semi-structured data to create a unified data record. The compute layer provides dedicated resources to enable users to access common data sets for many use cases without latency. The cloud services layer optimizes each use case's performance requirements with no administration. The company was founded by Marcin Zukowski, Thierry Cruanes, and Benoit Dageville on July 23, 2012 and is headquartered in Menlo Park, CA.

Snowflake Inc

Snowflake shares are surging after the company reported strong second-quarter financial results and raised its full-year guidance, with traders highlighting accelerating enterprise AI demand as a primary driver. While many investors are celebrating the growth, others remain skeptical about the sustainability of the rally, pointing to the company's lack of GAAP profitability and high valuation multiples.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath is trending as traders speculate on a potential short squeeze and a bullish re-rating ahead of upcoming earnings, with sentiment bolstered by recent analyst price target hikes and broader strength in the software sector. While some investors are optimistic about the company's shift toward agentic AI, others remain cautious, citing concerns over earnings execution and recent stock price volatility.

Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development, and commercialization of novel products for the treatment of genetic diseases. Its products include Crysvita, Mepsevii, Dojolvi, and Evkeeza. The company was founded by Emil D. Kakkis in April 2010 and is headquartered in Novato, CA.

Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc

Ultragenyx shares dropped sharply following the failure of its late-stage Aspire trial for GTX-102 in Angelman syndrome, leading to significant analyst downgrades. While some traders view the sell-off as an overreaction that creates a buying opportunity ahead of upcoming PDUFA catalysts, others express concern over the company's high spending and reliance on its remaining pipeline.

Hewlett Packard Enterprise Co. is a global edge-to-cloud company, which engages in the provision of information technology, technology and enterprise products, solutions, and services. It operates through the following segments: Server, Hybrid Cloud, Intelligent Edge, Financial Services, and Corporate Investments and Other. The Server segment consists of general-purpose servers for multi-workload computing and workload-optimized servers to deliver the performance and value for demanding applications, and integrated systems comprised of software and hardware designed to address high-performance computing and supercomputing, artificial intelligence, data analytics, and transaction processing workloads for government and commercial customers globally. The Hybrid Cloud segment is involved in a variety of cloud-native and hybrid solutions across storage, private cloud, and the infrastructure software-as-a-service space. The Intelligent Edge segment offers wired and wireless local area networks, campus, branch, and data center switching, software-defined wide-area-networks, private and public cellular network software, network security, and associated services that enable secure connectivity for businesses of any size. The Financial Services segment provides investment solutions, such as leasing, financing, IT consumption, utility programs, and asset management services for customers that facilitate technology deployment models and the acquisition of complete IT solutions, including hardware, software, and services from Hewlett Packard Enterprise and others. The Corporate Investments and Other segment includes the Advisory and Professional Services business, which primarily offers consultative-led services, HPE and partner technology expertise and advice, implementation services, as well as complex solution engagement capabilities, the Communications and Media Solutions business, which primarily offers software and related services to the telecommunications industry, and Hewlett Packard Labs, which is responsible for research and development. The company was founded by William R. Hewlett and David Packard on July 2, 1939 and is headquartered in Spring, TX.

Hewlett Packard Enterprise Co

Hewlett Packard Enterprise shares faced downward pressure following its third-quarter earnings report, as investors expressed concerns over margin moderation and supply-chain constraints despite a revenue and earnings beat. The community remains largely bullish, citing strong AI-driven growth, an expanded Oracle partnership, and positive analyst price target revisions, with many viewing the selloff as a potential entry opportunity.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovin is trending as traders debate whether the current price represents a significant undervaluation and a long-term opportunity following a recent correction, or if the stock is suffering from persistent technical manipulation. Many community members remain bullish, citing strong fundamental performance and the expectation of a recovery, while others express frustration over the stock's inability to sustain upward momentum compared to other tech and ad-tech peers.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

The SPY is trending as traders react to a relief rally spurred by Federal Reserve Governor Waller's comments suggesting potential interest rate stability, which helped calm inflation fears despite ongoing geopolitical tensions in the Middle East. While some market participants express frustration over perceived market manipulation and the disconnect between equity performance and economic data, others maintain a bullish outlook, citing AI-driven growth and a persistent 'buy-the-dip' mentality.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Marksans Pharma Gets USFDA Nod for Generic Tessalon Capsules

… infections. The approval strengthens Marksans Pharma ’s portfolio in the U.S … in the respiratory segment. Marksans Pharma Limited, headquartered in Mumbai, … manufacturing, and marketing of generic pharmaceutical formulations across global markets. The …

Marksans Pharma arm gets marketing nod for Cetirizine Dihydrochloride 1 mg/ml Oral Solution in UK

Mumbai: Marksans Pharma Limited has announced that its … mg Film-coated Tablets). Marksans Pharma Limited, headquartered at Mumbai, India … , manufacturing & marketing of generic pharmaceutical formulation in the global markets …

Brief Healthcare: IZOZF: Initiating Coverage: Breakthrough Technology for Breast Cancer Screening and more

In this briefing: IZOZF: Initiating Coverage: Breakthrough Technology for Breast Cancer Screening Fortis Healthcare Ltd - Strong Quarter with Margin Expansion Biocon Ltd - Resilient Momentum in Biosimilars Driving Growth The Beat Ideas: Marksans Pharma - USFDA's 'Zero Observation' Unlocks ₹3,000 Crore Goa Potential GENOVA (9341 JP): 1H FY03/26 flash update 1. IZOZF: Initiating Coverage: Breakthrough Technology for Breast Cancer Screening Izotropic is a medical device company that has developed an innovative machine that will allow for women to have more accurate and comfortable screenings for breast cancer. For years, women with dense breasts have had cancers missed or have had to undergo additional, expensive tests. With the Izotropic machine, costs for insurance companies will go down, accuracy will be greatly increased, and comfort will improve. 2. Fortis Healthcare Ltd - Strong Quarter with Margin Expansion Strong Revenue Growth Driven by Hospitals Segment: The Fortis Hospitals segment posted revenue of Rs 2,331 Cr, up 17.3% YoY and 7.6% QoQ, driven by the Hospital segment, which has reported 19.3% YoY growth, along with moderate growth in the Diagnostic Arm.

Brief Healthcare: Fortis Healthcare Ltd - Strong Quarter with Margin Expansion and more

In this briefing: Fortis Healthcare Ltd - Strong Quarter with Margin Expansion Biocon Ltd - Resilient Momentum in Biosimilars Driving Growth The Beat Ideas: Marksans Pharma - USFDA's 'Zero Observation' Unlocks ₹3,000 Crore Goa Potential GENOVA (9341 JP): 1H FY03/26 flash update Pfizer and Novo Nordisk’s $10bn battle over weight-loss drugs 1. Fortis Healthcare Ltd - Strong Quarter with Margin Expansion Strong Revenue Growth Driven by Hospitals Segment: The Fortis Hospitals segment posted revenue of Rs 2,331 Cr, up 17.3% YoY and 7.6% QoQ, driven by the Hospital segment, which has reported 19.3% YoY growth, along with moderate growth in the Diagnostic Arm. Stable ARPOB and Occupancy: ARPOB stood at Rs 68,800, marking a 5.9% YoY increase, while occupancy rose to 71% (up 100 bps QoQ), supported by a 13% YoY growth in occupied bed days. EBITDA margin expanded to 23.9%, up 200 bps YoY and 120 bps QoQ. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only.

Brief India: RITES Ltd - Strong Orderbook to Drive Growth and more

In this briefing: RITES Ltd - Strong Orderbook to Drive Growth Biocon Ltd - Resilient Momentum in Biosimilars Driving Growth Telecom Industry Snapshot- September 2025: Jio and Airtel Drive Data-Led Growth UPI’s Next Act: How Credit Lines Could Reshape India’s Retail Lending Landscape The Beat Ideas: Marksans Pharma - USFDA's 'Zero Observation' Unlocks ₹3,000 Crore Goa Potential 1. RITES Ltd - Strong Orderbook to Drive Growth Strong Order Book: In Q2FY26, the company secured over 150 new orders worth Rs 851 Cr, taking the total order book to Rs 9,090 Cr and ensuring strong revenue visibility for the next 2–2.5 years. Notably, 34% of the order book comprises the high-margin consultancy segment, underscoring its profitability profile. Backed by a robust pipeline and increasing opportunities across the infrastructure space, the company remains well-positioned to deliver sustainable long-term growth. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only.

Brief Growth Ideas: BMP [BUY +20.3%] - 2026F Earnings to Hit New Record High on Weak Input Costs and more

In this briefing: BMP [BUY +20.3%] - 2026F Earnings to Hit New Record High on Weak Input Costs GAS [BUY +25.0%] - Strong Volume Recovery to Boost 2026 Core NPAT KDH [BUY +42.2%] - Strong Land Bank Monetization to Boost Earnings Growth Silergy (6415.TT): 4Q25 Flat or Slightly Upside; Early Gen4 Yields Remain Non-Comparable. The Beat Ideas: Marksans Pharma - USFDA's 'Zero Observation' Unlocks ₹3,000 Crore Goa Potential 1. BMP [BUY +20.3%] - 2026F Earnings to Hit New Record High on Weak Input Costs We upgrade our rating for BMP to BUY from OUTPERFORM and raise our target price (TP) by 24% to VND192,500/share. The share price has risen 14% over the past two months. Our higher TP is due to (1) rolling our TP forward to end-2026 and (2) raising our 2026-30F NPAT-MI forecasts by ~20% each year. The higher earnings forecast is mainly driven by our higher GPM forecasts of ~3.5 percentage points each year during this period, respectively. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only.

Brief Growth Ideas: KDH [BUY +42.2%] - Strong Land Bank Monetization to Boost Earnings Growth and more

In this briefing: KDH [BUY +42.2%] - Strong Land Bank Monetization to Boost Earnings Growth Silergy (6415.TT): 4Q25 Flat or Slightly Upside; Early Gen4 Yields Remain Non-Comparable. The Beat Ideas: Marksans Pharma - USFDA's 'Zero Observation' Unlocks ₹3,000 Crore Goa Potential Primer: Tracxn Technologies (TRACXN IN) - Nov 2025 Primer: Hyundai Engineering (064540 KS) - Nov 2025 1. KDH [BUY +42.2%] - Strong Land Bank Monetization to Boost Earnings Growth We reiterate our BUY rating for KDH and raise our target price (TP) by 3% to VND48,500/share. Our higher TP is mainly driven by a higher valuation for Binh Trung Dong, increased book value for undisclosed pipeline, and rolling our TP horizon forward to end-2026. We forecast 2025F NPAT-MI of VND1.04tn (USD39.5mn; +29% YoY; +1% vs prior), with Q4 2025F NPAT-MI of VND484bn (USD18mn; 2x QoQ and +22% YoY), driven by continued handovers of presold low-rise units at ‘Gladia by the Waters’ (11.8 ha; JV with Keppel; KDH 51%). Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only.

Brief Equities Bottom-Up: KDH [BUY +42.2%] - Strong Land Bank Monetization to Boost Earnings Growth and more

In this briefing: KDH [BUY +42.2%] - Strong Land Bank Monetization to Boost Earnings Growth Silergy (6415.TT): 4Q25 Flat or Slightly Upside; Early Gen4 Yields Remain Non-Comparable. Coupang: Facing Increasing Risk of a Potential Ban on Early Dawn Deliveries - Number One Risk Factor Topline Flash Note: Bank of Punjab (BOP): Corporate Briefing Key Takeaways The Beat Ideas: Marksans Pharma - USFDA's 'Zero Observation' Unlocks ₹3,000 Crore Goa Potential 1. KDH [BUY +42.2%] - Strong Land Bank Monetization to Boost Earnings Growth We reiterate our BUY rating for KDH and raise our target price (TP) by 3% to VND48,500/share. Our higher TP is mainly driven by a higher valuation for Binh Trung Dong, increased book value for undisclosed pipeline, and rolling our TP horizon forward to end-2026. We forecast 2025F NPAT-MI of VND1.04tn (USD39.5mn; +29% YoY; +1% vs prior), with Q4 2025F NPAT-MI of VND484bn (USD18mn; 2x QoQ and +22% YoY), driven by continued handovers of presold low-rise units at ‘Gladia by the Waters’ (11.8 ha; JV with Keppel; KDH 51%).

Brief India: UPI’s Next Act: How Credit Lines Could Reshape India’s Retail Lending Landscape and more

In this briefing: UPI’s Next Act: How Credit Lines Could Reshape India’s Retail Lending Landscape The Beat Ideas: Marksans Pharma - USFDA's 'Zero Observation' Unlocks ₹3,000 Crore Goa Potential Capillary Technologies India IPO- Forensic Analysis Primer: Tracxn Technologies (TRACXN IN) - Nov 2025 Shadowfax Technologies Pre-IPO Tearsheet 1. UPI’s Next Act: How Credit Lines Could Reshape India’s Retail Lending Landscape RBI and NPCI are rolling out the Credit Line on UPI (CLOU) , allowing instant digital credit within UPI apps- effectively merging payments and lending. CLOU leverages India’s most trusted digital infrastructure to expand formal credit access , especially for new-to-credit consumers , and could be the foundation for a data-driven lending model. By combining UPI Credit Lines with a forthcoming Digital Payment Score (DPS) , India may transition from a payments-led to a credit-led digital economy - redefining financial inclusion and retail lending economics. 2. The Beat Ideas: Marksans Pharma - USFDA's 'Zero Observation' Unlocks ₹3,000 Crore Goa Potential Marksans Pharma's new, capacity-doubling Goa facility (acquired from Teva) just received a ' Zero 483 Observation' clearance from the USFDA , completely de-risking its largest-ever capex.

Brief Growth Ideas: Silergy (6415.TT): 4Q25 Flat or Slightly Upside; Early Gen4 Yields Remain Non-Comparable. and more

In this briefing: Silergy (6415.TT): 4Q25 Flat or Slightly Upside; Early Gen4 Yields Remain Non-Comparable. The Beat Ideas: Marksans Pharma - USFDA's 'Zero Observation' Unlocks ₹3,000 Crore Goa Potential Primer: Tracxn Technologies (TRACXN IN) - Nov 2025 Primer: Hyundai Engineering (064540 KS) - Nov 2025 Primer: Zedcor (ZDC CN) - Nov 2025 1. Silergy (6415.TT): 4Q25 Flat or Slightly Upside; Early Gen4 Yields Remain Non-Comparable. 4Q25 seasonal outlook? Silergy expects flat to slightly up QoQ, similar to past years. Silergy does see consolidation, and given its stronger financials, product breadth, and R&D capabilities, the company remains a top supplier and will continue to gain share. Will 1H next year be better than 2H this year?Hard to say because of Chinese New Year seasonality.We expect YoY growth, but not strong yet. 2. The Beat Ideas: Marksans Pharma - USFDA's 'Zero Observation' Unlocks ₹3,000 Crore Goa Potential Marksans Pharma's new, capacity-doubling Goa facility (acquired from Teva) just received a ' Zero 483 Observation' clearance from the USFDA , completely de-risking its largest-ever capex.

Marksans Pharma Ltd. engages in the research, manufacture, marketing, and sale of pharmaceutical formulations. Its product portfolio includes tablets, hard capsules, soft gelatin capsules, oral liquids, and ointments. It operates through the following geographical segments: US and North America, Europe and UK, Australia and New Zealand, India, and Rest of World. The company was founded by Mark Bosco Saldanha on April 16, 1992 and is headquartered in Mumbai, India.

Current Price	332.55
Prev Close	334.10
Open	334.30
Dividend Yield	0.57%
50-Day Moving Average	285.03
Beta	N/A
Avg. Volume	5.73M
PE Ratio	29.13

52-Week High	345.50
52-Week Low	155.00
Market Capitalization	150.68B
EPS (Annual)	9.22
Price to Book	4.98
Revenue Per Employee	17.48M

Feed

News

Sentiment

Fundamentals

Info